VR Pilot for Pancreatitis Pain
This study is testing if a home-based virtual reality (VR) program can help adults with chronic pancreatitis (CP) pain. CP is a long-lasting inflammation of the pancreas that causes severe pain. The study will compare two VR experiences: one called "Gut Directed VR" which uses a specific therapy, and another called "Sham Control VR" which uses distracting games. Researchers want to see if using VR at home is practical and if it helps with pain and daily life. You might be able to join if you are 18 to 75 years old, have a diagnosis of CP, and experience significant abdominal pain. The study plans to enroll 20 participants, but its current status is unclear.
- Study design
- This is an interventional study with 20 planned participants, comparing two types of virtual reality experiences.
- What's involved
- You will complete questionnaires and provide biometric data from a Fitbit. The study lasts for 8 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed until the end of the study, which is 8 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
VR Pilot for Pancreatitis
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Feasibility of home-based VREnd of study (8 Weeks)
The primary objective of this study is to determine the feasibility of a home-based, standardized, gut-directed, virtual reality cognitive behavioral therapy (VR CBT) on clinical and functional outcomes of patients with chronic pain from chronic pancreatitis (CP) based on subject's ability to adhere to and complete the study. Feasibility will be met if ≥75% of enrolled patients complete the 8-week study.